GB201016403D0 - Novel interaction between staphylococcus aureus Sbi and C3d protiens - Google Patents

Novel interaction between staphylococcus aureus Sbi and C3d protiens

Info

Publication number
GB201016403D0
GB201016403D0 GB201016403A GB201016403A GB201016403D0 GB 201016403 D0 GB201016403 D0 GB 201016403D0 GB 201016403 A GB201016403 A GB 201016403A GB 201016403 A GB201016403 A GB 201016403A GB 201016403 D0 GB201016403 D0 GB 201016403D0
Authority
GB
United Kingdom
Prior art keywords
sbi
staphylococcus aureus
protiens
interaction
novel interaction
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GB201016403A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BATH VENTURES
Original Assignee
BATH VENTURES
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by BATH VENTURES filed Critical BATH VENTURES
Priority to GB201016403A priority Critical patent/GB201016403D0/en
Publication of GB201016403D0 publication Critical patent/GB201016403D0/en
Priority to PCT/GB2011/001414 priority patent/WO2012042213A1/en
Ceased legal-status Critical Current

Links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Biochemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)

Abstract

The invention relates to the Sbi protein of Staphylococcus aureus, and in particular to the interaction between Sbi and the complement protein C3d. The crystal structure of the Sbi-C3d complex reveals an unexpected interaction between Sbi and the convex surface of C3d, which suggests that particular fragments and variants of Sbi may have utility as inhibitors of the alternative complement pathway. The invention provides novel peptides and their use in the inhibition of inflammatory conditions characterised by undesirable activation of the complement pathway.
GB201016403A 2010-09-29 2010-09-29 Novel interaction between staphylococcus aureus Sbi and C3d protiens Ceased GB201016403D0 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
GB201016403A GB201016403D0 (en) 2010-09-29 2010-09-29 Novel interaction between staphylococcus aureus Sbi and C3d protiens
PCT/GB2011/001414 WO2012042213A1 (en) 2010-09-29 2011-09-29 Novel interaction between staphylococcus aureus sbi and c3d proteins

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB201016403A GB201016403D0 (en) 2010-09-29 2010-09-29 Novel interaction between staphylococcus aureus Sbi and C3d protiens

Publications (1)

Publication Number Publication Date
GB201016403D0 true GB201016403D0 (en) 2010-11-10

Family

ID=43128179

Family Applications (1)

Application Number Title Priority Date Filing Date
GB201016403A Ceased GB201016403D0 (en) 2010-09-29 2010-09-29 Novel interaction between staphylococcus aureus Sbi and C3d protiens

Country Status (2)

Country Link
GB (1) GB201016403D0 (en)
WO (1) WO2012042213A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112023017749A2 (en) 2021-03-04 2023-10-03 Helix Nanotechnologies Inc COMPOSITIONS INCLUDING SBI ADJUVANTS AND METHODS OF USE THEREOF

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0134215B1 (en) 1982-08-27 1989-10-25 EKINS, Roger Philip Measurement of analyte concentration
ATE86385T1 (en) 1986-08-06 1993-03-15 Multilyte Ltd DETERMINING ANALYTE CONCENTRATION WITH TWO LABELS.
GB8803000D0 (en) 1988-02-10 1988-03-09 Ekins Roger Philip Determination of ambient concentrations of several analytes
GB8810400D0 (en) 1988-05-03 1988-06-08 Southern E Analysing polynucleotide sequences
WO1993008472A1 (en) 1991-10-15 1993-04-29 Multilyte Limited Binding assay employing labelled reagent
GB9326450D0 (en) 1993-12-24 1994-02-23 Multilyte Ltd Binding assay
GB9326451D0 (en) 1993-12-24 1994-02-23 Multilyte Ltd Binding assay
GB9404709D0 (en) 1994-03-11 1994-04-27 Multilyte Ltd Binding assay
EP2021087B1 (en) 2006-05-30 2010-09-15 Iknowledge Ltd. Method and apparatus for televising a card game
GB0610776D0 (en) * 2006-05-31 2006-07-12 Univ Bath Novel applications for staphylococcus aureus Sbi protein

Also Published As

Publication number Publication date
WO2012042213A1 (en) 2012-04-05

Similar Documents

Publication Publication Date Title
EP3725811A3 (en) Compositions for inhibiting masp-2 dependent complement activation
PH12019502809A1 (en) Substituted tricyclic compounds as fgfr inhibitors
JOP20180102B1 (en) Pharmaceutical composition
AU2018253639A1 (en) Compositions and methods for antibodies targeting EPO
BR112014015908A2 (en) composition
WO2015028969A3 (en) Transduction buffer
HK1205201A1 (en) Proteins comprising mrsa pbp2a and fragments thereof, nucleic acids encoding the same, and compositions and their use to prevent and treat mrsa infections mrsa pbp2a mrsa
EP3470526A3 (en) Antibodies that specifically bind staphylococcus aureus alpha toxin and methods of use
GT201400057A (en) 3-PIRMIDIN-4-IL-OXAZOLIDIN-2-ONAS AS INHIBITORS OF THE MUTANT HDI
GT201300136A (en) TREATMENT METHODS WITH BCL-2 SELECTIVE INHIBITORS
MX2018009524A (en) Arginine - free tnfr : fc- fusion polypeptide compositions and methods of use.
MX340831B (en) Pesticidal compositions.
EP2585110A4 (en) Antibodies to the c3d fragment of complement component 3
MY165618A (en) Staphylococcus aureus leukocidins, therapeutic compositions, and uses thereof
EA019744B9 (en) Isothiazolyloxyphenyl amidines and use thereof for combating fungi and seed material treated with isothiazolyloxyphenyl amidines
PH12014501323B1 (en) Compositions comprising lignin
PH12014501410A1 (en) Compositions and methods for antibodies targeting factor p
UA106900C2 (en) LibreOfficeDR5-BINDING POLYPEPTIDE
WO2012050611A3 (en) Aptamers to glycoprotein vi
WO2013169631A3 (en) Wnt protein signalling inhibitors
GEP201606514B (en) Apoptosis inhibitors and usage thereof
WO2013022550A3 (en) Small molecule inhibitors of ebola and lassa fever viruses
EP2576536A4 (en) Haematopoietic-prostaglandin d2 synthase inhibitors
WO2012020108A3 (en) Multimeric inhibitors of viral fusion and uses thereof
GB201118201D0 (en) Novel peptides

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)